Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.35), $0.06 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $61.7 million versus the consensus estimate of $44.22 million.

GUIDANCE:

Akebia Therapeutics sees FY2022 revenue of $165-170 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.